Key Takeaways Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's ...

Amgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data ...

After Sezzle (SEZL) rallied from $200 to over $400, the stock lost 13.87% on Tuesday. The stock drop could continue, depending on how many investors sell to lock in their profits. Sezzle has strong ...

THOUSAND OAKS, Calif., Oct. 30, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2024.

If you’re on the fence about investing in Amgen Inc or Pfizer Inc because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision. Read on to ...

In the third quarter, Amgen continued advancing two of its investigational precision oncology drugs, PRMT5 inhibitor AMG 193 and anti-FGFR2b agent bemarituzumab, into later stage trials. In Q3, the ...

(RTTNews) - Amgen Inc. (AMGN) reported earnings for its third quarter that increased from the same period last year and beat the Street estimates. The company's bottom line came in at $2.83 ...

* The known adjustments are presented net of their related tax impact, which amount to approximately $2.39 per share. (a) The adjustments primarily include noncash amortization of intangible assets ...

* The known adjustments are presented net of their related tax impact, which amount to approximately $2.39 per share. (a) The adjustments primarily include noncash amortization of intangible ...